{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:23:21Z","timestamp":1790659401500,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03616-1","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:22:22Z","timestamp":1784103742000},"page":"4395-4416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing Extended Adjuvant Endocrine Therapy in Early HR+\/HER2\u2212\u2009Breast Cancer: The Emerging Role of Genomic Assays and ctDNA MRD"],"prefix":"10.1007","volume":"43","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5706-4450","authenticated-orcid":false,"given":"Xiaohong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"6","key":"3616_CR1","first-page":"438","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438\u201351.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"3616_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s12094-025-04026-5","volume":"28","author":"J Hou","year":"2026","unstructured":"Hou J, et al. Hotspots and future trends of male breast cancer: a global perspective. Clin Transl Oncol. 2026;28(2):541\u201356.","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"3616_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001720","volume":"11","author":"A Eng","year":"2014","unstructured":"Eng A, McCormack V, dos-Santos-Silva I. Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis. PLoS Med. 2014;11(9):e1001720.","journal-title":"PLoS Med"},{"key":"3616_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103451","volume":"69","author":"N Chic","year":"2021","unstructured":"Chic N, et al. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. EBioMedicine. 2021;69:103451.","journal-title":"EBioMedicine"},{"issue":"6","key":"3616_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/CCO.0000000000001085","volume":"36","author":"L Ascione","year":"2024","unstructured":"Ascione L, et al. Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives. Curr Opin Oncol. 2024;36(6):465\u201373.","journal-title":"Curr Opin Oncol"},{"issue":"11","key":"3616_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.26921","volume":"3","author":"C Cullinane","year":"2020","unstructured":"Cullinane C, et al. Association of circulating tumor DNA with disease-free survival in breast cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(11):e2026921.","journal-title":"JAMA Netw Open"},{"key":"3616_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153813","author":"M Shoukry","year":"2021","unstructured":"Shoukry M, et al. The emerging role of circulating tumor DNA in the management of breast cancer. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13153813.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"3616_CR8","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1158\/1078-0432.CCR-19-3005","volume":"26","author":"HA Parsons","year":"2020","unstructured":"Parsons HA, et al. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin Cancer Res. 2020;26(11):2556\u201364.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3616_CR9","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.1097\/JS9.0000000000001779","volume":"110","author":"Z Bi","year":"2024","unstructured":"Bi Z, et al. Optimized treatment strategy for early-stage medium\/high-risk hormone receptor-positive\/HER2\u2212negative breast cancer. Int J Surg. 2024;110(12):7590\u20132.","journal-title":"Int J Surg"},{"issue":"Suppl 1","key":"3616_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-008-0232-x","volume":"112","author":"J Gligorov","year":"2008","unstructured":"Gligorov J, Lotz JP. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2\u2212negative metastatic breast cancer. Breast Cancer Res Treat. 2008;112(Suppl 1):53\u201366.","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"3616_CR11","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1158\/1078-0432.CCR-23-4020","volume":"30","author":"M Bottosso","year":"2024","unstructured":"Bottosso M, et al. Gene expression assays to tailor adjuvant endocrine therapy for HR+\/HER2\u2212 breast cancer. Clin Cancer Res. 2024;30(14):2884\u201394.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3616_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-023-07227-0","volume":"205","author":"L Licata","year":"2024","unstructured":"Licata L, et al. Real-world use of multigene signatures in early breast cancer: differences to clinical trials. Breast Cancer Res Treat. 2024;205(1):39\u201348.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"3616_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1245\/s10434-017-6254-z","volume":"25","author":"OM Fayanju","year":"2018","unstructured":"Fayanju OM, Park KU, Lucci A. Molecular genomic testing for breast cancer: utility for surgeons. Ann Surg Oncol. 2018;25(2):512\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"3616_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2023.7087","volume":"22","author":"TB Sanft","year":"2024","unstructured":"Sanft TB, et al. Impact of the Breast Cancer Index for extended endocrine decision-making: first results of the prospective BCI registry study. J Natl Compr Canc Netw. 2024;22(2):99\u2013107.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"3616_CR15","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1158\/1078-0432.CCR-23-1977","volume":"30","author":"EP Mamounas","year":"2024","unstructured":"Mamounas EP, et al. Breast Cancer Index and prediction of extended aromatase inhibitor therapy benefit in hormone receptor-positive breast cancer from the NRG Oncology\/NSABP B-42 trial. Clin Cancer Res. 2024;30(9):1984\u201391.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3616_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13058-022-01589-x","volume":"24","author":"DC Sgroi","year":"2022","unstructured":"Sgroi DC, et al. Correlative studies of the Breast Cancer Index (HOXB13\/IL17BR) and ER, PR, AR, AR\/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Breast Cancer Res. 2022;24(1):90.","journal-title":"Breast Cancer Res"},{"issue":"10","key":"3616_CR17","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/s41588-023-01507-7","volume":"55","author":"X Jin","year":"2023","unstructured":"Jin X, et al. Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat Genet. 2023;55(10):1696\u2013708.","journal-title":"Nat Genet"},{"issue":"22","key":"3616_CR18","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1200\/JCO.22.00908","volume":"40","author":"M Lipsyc-Sharf","year":"2022","unstructured":"Lipsyc-Sharf M, et al. Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, Human Epidermal Growth Factor Receptor 2-negative breast cancer. J Clin Oncol. 2022;40(22):2408\u201319.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3616_CR19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","volume":"41","author":"MJM Magbanua","year":"2023","unstructured":"Magbanua MJM, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023;41(6):1091-1102.e4.","journal-title":"Cancer Cell"},{"issue":"19","key":"3616_CR20","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836\u201346.","journal-title":"N Engl J Med"},{"issue":"5","key":"3616_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41571-018-0145-5","volume":"16","author":"J Richman","year":"2019","unstructured":"Richman J, Dowsett M. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nat Rev Clin Oncol. 2019;16(5):296\u2013311.","journal-title":"Nat Rev Clin Oncol"},{"key":"3616_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ctrv.2018.07.015","volume":"70","author":"RD Bense","year":"2018","unstructured":"Bense RD, et al. Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. Cancer Treat Rev. 2018;70:118\u201326.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"3616_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10549-024-07509-1","volume":"209","author":"M Ito","year":"2025","unstructured":"Ito M, et al. Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy. Breast Cancer Res Treat. 2025;209(3):503\u201312.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"3616_CR24","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2019;30(8):1194\u2013220.","journal-title":"Ann Oncol"},{"issue":"1","key":"3616_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41523-022-00448-4","volume":"8","author":"R Yoder","year":"2022","unstructured":"Yoder R, et al. Impact of low versus negative estrogen\/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer. npj Breast Cancer. 2022;8(1):80.","journal-title":"npj Breast Cancer"},{"issue":"9869","key":"3616_CR26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies C, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805\u201316.","journal-title":"Lancet"},{"issue":"18_suppl","key":"3616_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1200\/jco.2013.31.18_suppl.5","volume":"31","author":"RG Gray","year":"2013","unstructured":"Gray RG, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31(18_suppl):5\u20135.","journal-title":"J Clin Oncol"},{"key":"3616_CR28","doi-asserted-by":"publisher","first-page":"175883591877692","DOI":"10.1177\/1758835918776923","volume":"10","author":"MB Suter","year":"2018","unstructured":"Suter MB, Pagani O. Should age impact breast cancer management in young women? Fine tuning of treatment guidelines. Ther Adv Med Oncol. 2018;10:1758835918776923.","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"3616_CR29","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1200\/JCO.22.01065","volume":"41","author":"PA Francis","year":"2023","unstructured":"Francis PA, et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 2023;41(7):1370\u20135.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3616_CR30","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jamaoncol.2024.3044","volume":"10","author":"RM O'Regan","year":"2024","unstructured":"O\u2019Regan RM, et al. Breast cancer index in premenopausal women with early-stage hormone receptor-positive breast cancer. JAMA Oncol. 2024;10(10):1379\u201389.","journal-title":"JAMA Oncol"},{"issue":"7","key":"3616_CR31","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.22.01064","volume":"41","author":"O Pagani","year":"2023","unstructured":"Pagani O, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol. 2023;41(7):1376\u201382.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3616_CR32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.19.00126","volume":"38","author":"HA Kim","year":"2020","unstructured":"Kim HA, et al. Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial. J Clin Oncol. 2020;38(5):434\u201343.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3616_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77\u201390.","journal-title":"Lancet Oncol"},{"key":"3616_CR34","doi-asserted-by":"crossref","unstructured":"Gradishar WJ et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(5):331\u2013357.","DOI":"10.6004\/jnccn.2024.0035"},{"issue":"1","key":"3616_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","volume":"9","author":"JF Forbes","year":"2008","unstructured":"Forbes JF, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45\u201353.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3616_CR36","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398. J Clin Oncol. 2007;25(5):486\u201392.","journal-title":"J Clin Oncol"},{"issue":"9561","key":"3616_CR37","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","volume":"369","author":"RC Coombes","year":"2007","unstructured":"Coombes RC, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369(9561):559\u201370.","journal-title":"Lancet"},{"issue":"9484","key":"3616_CR38","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","volume":"366","author":"R Jakesz","year":"2005","unstructured":"Jakesz R, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366(9484):455\u201362.","journal-title":"Lancet"},{"issue":"12","key":"3616_CR39","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135\u201341.","journal-title":"Lancet Oncol"},{"key":"3616_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918777437","volume":"10","author":"E Munzone","year":"2018","unstructured":"Munzone E, Colleoni M. Optimal management of luminal breast cancer: how much endocrine therapy is long enough? Ther Adv Med Oncol. 2018;10:1758835918777437.","journal-title":"Ther Adv Med Oncol"},{"key":"3616_CR41","doi-asserted-by":"crossref","unstructured":"Bekes I, Huober J. Extended adjuvant endocrine therapy in early breast cancer patients\u2014review and perspectives. Cancers (Basel). 2023;15(16).","DOI":"10.3390\/cancers15164190"},{"issue":"11","key":"3616_CR42","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/jnci\/djad078","volume":"115","author":"EP Mamounas","year":"2023","unstructured":"Mamounas EP, et al. Ten-year update: NRG Oncology\/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst. 2023;115(11):1302\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"3616_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209\u201319.","journal-title":"N Engl J Med"},{"issue":"2","key":"3616_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"3616_CR45","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","volume":"22","author":"M Piccart","year":"2021","unstructured":"Piccart M, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021;22(4):476\u201388.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3616_CR46","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdz289","volume":"30","author":"JMS Bartlett","year":"2019","unstructured":"Bartlett JMS, et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol. 2019;30(11):1776\u201383.","journal-title":"Ann Oncol"},{"issue":"2","key":"3616_CR47","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10549-019-05226-8","volume":"176","author":"I Sestak","year":"2019","unstructured":"Sestak I, et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019;176(2):377\u201386.","journal-title":"Breast Cancer Res Treat"},{"key":"3616_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.896431","volume":"12","author":"H Wang","year":"2022","unstructured":"Wang H, et al. RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients. Front Oncol. 2022;12:896431.","journal-title":"Front Oncol"},{"issue":"3","key":"3616_CR49","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10549-023-07149-x","volume":"203","author":"KM Woolpert","year":"2024","unstructured":"Woolpert KM, et al. Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2024;203(3):407\u201317.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"3616_CR50","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1158\/1078-0432.CCR-21-3385","volume":"28","author":"JMS Bartlett","year":"2022","unstructured":"Bartlett JMS, et al. Breast Cancer Index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the Trans-aTTom study. Clin Cancer Res. 2022;28(9):1871\u201380.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"3616_CR51","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1200\/JCO.22.00577","volume":"41","author":"T Iwase","year":"2023","unstructured":"Iwase T, et al. Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial. J Clin Oncol. 2023;41(18):3329\u201338.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3616_CR52","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(18)30621-1","volume":"20","author":"EP Mamounas","year":"2019","unstructured":"Mamounas EP, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology\/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(1):88\u201399.","journal-title":"Lancet Oncol"},{"issue":"30","key":"3616_CR53","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1200\/JCO.23.01995","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi P, et al. Utility of the 70-Gene MammaPrint assay for prediction of benefit from extended letrozole therapy in the NRG Oncology\/NSABP B-42 trial. J Clin Oncol. 2024;42(30):3561\u20139.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3616_CR54","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1038\/bjc.2013.671","volume":"109","author":"P Dubsky","year":"2013","unstructured":"Dubsky P, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2- breast cancer patients. Br J Cancer. 2013;109(12):2959\u201364.","journal-title":"Br J Cancer"},{"issue":"9","key":"3616_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103687","volume":"9","author":"R Cutts","year":"2024","unstructured":"Cutts R, et al. Association of post-operative ctDNA detection with outcomes of patients with early breast cancers. ESMO Open. 2024;9(9):103687.","journal-title":"ESMO Open"},{"issue":"16","key":"3616_CR56","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker JD, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol. 2018;36(16):1631\u201341.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3616_CR57","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","volume":"25","author":"P Razavi","year":"2019","unstructured":"Razavi P, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928\u201337.","journal-title":"Nat Med"},{"issue":"302","key":"3616_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aab0021","volume":"7","author":"I Garcia-Murillas","year":"2015","unstructured":"Garcia-Murillas I, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133.","journal-title":"Sci Transl Med"},{"issue":"10","key":"3616_CR59","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.2174\/1389450121666200312105908","volume":"21","author":"A Gouri","year":"2020","unstructured":"Gouri A, et al. Prediction of late recurrence and distant metastasis in early-stage breast cancer: overview of current and emerging biomarkers. Curr Drug Targets. 2020;21(10):1008\u201325.","journal-title":"Curr Drug Targets"},{"issue":"1","key":"3616_CR60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13058-015-0516-0","volume":"17","author":"I Sestak","year":"2015","unstructured":"Sestak I, Cuzick J. Markers for the identification of late breast cancer recurrence. Breast Cancer Res. 2015;17(1):10.","journal-title":"Breast Cancer Res"},{"issue":"14","key":"3616_CR61","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","volume":"25","author":"RC Coombes","year":"2019","unstructured":"Coombes RC, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25(14):4255\u201363.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3616_CR62","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","volume":"11","author":"EJ Moding","year":"2021","unstructured":"Moding EJ, et al. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 2021;11(12):2968\u201386.","journal-title":"Cancer Discov"},{"key":"3616_CR63","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1200\/JCO.2025.43.16_suppl.1009","volume":"43","author":"N Hunter","year":"2025","unstructured":"Hunter N, et al. Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial). J Clin Oncol. 2025;43:1009\u20131009.","journal-title":"J Clin Oncol."},{"key":"3616_CR64","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1200\/JCO.2025.43.16_suppl.1010","volume":"43","author":"L Pusztai","year":"2025","unstructured":"Pusztai L, et al. Circulating tumor (ct)DNA monitoring of ER+\/HER2- high-risk breast cancer during adjuvant endocrine therapy. J Clin Oncol. 2025;43:1010\u20131010.","journal-title":"J Clin Oncol."},{"key":"3616_CR65","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2025.43.16_suppl.1011","volume":"43","author":"P Razavi","year":"2025","unstructured":"Razavi P, et al. Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC). J Clin Oncol. 2025;43:1011\u20131011.","journal-title":"J Clin Oncol."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03616-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03616-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03616-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:22:22Z","timestamp":1790655742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03616-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3616"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03616-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors (Yang Liu, Mengxiao Wang, Dongsheng Chen, Yuan Tan, Xing Zhang, Xiaohong Wang) declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}